Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the manufacturing, supply, and importation of therapeutic goods in Australia, ensuring that these products are of acceptable quality, efficacy, and safety. The Act was introduced to address the need for a comprehensive regulatory framework governing therapeutic goods, aiming to protect public health by maintaining high standards in the industry. This legislation is administered by the Therapeutic Goods Administration, which operates under the auspices of the Department of Health. The policy objective underlying the Act is to safeguard the health and safety of the Australian public by ensuring that therapeutic goods are safe, effective, and of high quality. In this context, the Act empowers the Secretary to take action such as suspending manufacturing licenses when necessary to uphold these standards. On 15 January 2021, Katherine Clark, acting as the Delegate of the Secretary, published details regarding the suspension of a licence to manufacture therapeutic goods. Specifically, GD Pharma Pty Ltd's licence, number MI-2012-LI-00154-3, located at 46a Beulah Road, Norwood, SA, 5067, was suspended from 20 November 2020 to 24 March 2021, following a request from the manufacturer. This action was taken under Section 41(1)(d) of the Therapeutic Goods Act 1989, reflecting the authority granted to the Secretary to manage and oversee the manufacturing of therapeutic goods to ensure compliance with the Act's stringent quality and safety requirements.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity involved in the manufacture, importation, supply, or distribution of therapeutic goods within Australia. This includes pharmaceuticals, medical devices, blood, and tissues. The Act extends to the entire Commonwealth, thereby applying uniformly across all states and territories. It also covers therapeutic goods that are exported from Australia. The Act includes provisions that allow the Secretary to suspend or cancel licenses of manufacturers who fail to meet the required standards. In the provided example, GD Pharma Pty Ltd's license was suspended under Section 41(1)(d) of the Act due to specific concerns that led to the suspension from 20 November 2020 to 24 March 2021. The Act also provides for various exclusions and exemptions, although specific instances are detailed in subordinate legislation, which can further elaborate on the scope and application of the primary Act.

Key Provisions

The key provision of this legislative instrument under Section 41(1)(d) of the Therapeutic Goods Act 1989 (the Act) concerns the suspension of a licence to manufacture therapeutic goods. Specifically, this notice details the suspension of the Licence held by GD Pharma Pty Ltd, with the licence number MI-2012-LI-00154-3, located at 46a Beulah Road, Norwood, SA, 5067. The suspension, which is effective from 20 November 2020 to 24 March 2021, was requested by the manufacturer themselves. This means that during this period, GD Pharma Pty Ltd is not permitted to manufacture any therapeutic goods that would normally require a licence under the Act. The obligations imposed by this notice on GD Pharma Pty Ltd include ceasing all activities related to the manufacture of therapeutic goods for the duration of the suspension. This ensures that the company does not produce any goods that may not meet the required standards or specifications during this period. Additionally, the company must comply with any further instructions or requirements that may be communicated by the Therapeutic Goods Administration (TGA) during or after the suspension period. The Therapeutic Goods Act 1989 provides for various offences and penalties for breaches of its provisions. For example, Section 25 of the Act imposes criminal penalties for offences such as manufacturing therapeutic goods without a licence, or manufacturing goods that do not comply with the standards set out in the Act. In the case of this notice, while the licence is suspended, any continued manufacturing activities by GD Pharma Pty Ltd could potentially lead to criminal charges under the Act. Furthermore, any failure to comply with the terms of the suspension or any additional requirements imposed by the TGA could result in further administrative or legal consequences. The maximum penalties for offences under the Therapeutic Goods Act 1989 can be significant. For instance, individuals and companies found guilty of manufacturing therapeutic goods without a licence or in a manner that breaches the Act may face fines up to $1.1 million for individuals and $5.5 million for corporations, as well as potential imprisonment terms. These stringent penalties underscore the importance of adhering to the Act's provisions and the seriousness with which the TGA and the courts treat any breaches. The notice serves as a formal warning to GD Pharma Pty Ltd and other entities governed by the Act to comply with all relevant requirements to avoid these severe consequences.